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Abstract 
 
Objective: To compare the proportion of clinically significant prostate cancers (PCa) found 
in lesions detected by multiparametric MRI (mpMRI) with that found in lesions detected by 
multiparametric ultrasound (mpUSS), in men at risk. 
 
Patients and Methods: CADMUS (Cancer Detection by Multiparametric Ultrasound of the 
prostate) is a prospective, multi-centre paired cohort diagnostic utility study with built-in 
randomisation of order of biopsies. The trial is registered ISRCTN38541912. All patients will 
undergo the index test under evaluation (mpUSS +/-biopsies), as well as the standard test 
(mpMRI +/-biopsies). Eligible men will be those at risk of harbouring prostate cancer usually 
recommended for prostate biopsy, either for the first time or as a repeat, who have not had 
any prior treatment for prostate cancer. Men in need of repeat biopsy will include those with 
prior negative results but ongoing suspicion, and those with an existing prostate cancer 
diagnosis but a need for accurate risk stratification. Both scans will be reported blind to the 
results of the other and the order in which the targeted biopsies derived from the two 
different imaging modalities are taken will be randomised. Comparison will be drawn 
between biopsy results of lesions detected by mpUSS with those lesions detected by mpMRI. 
Agreement over position between the two imaging modalities will be studied. 
 
Discussion: CADMUS will provide level one evidence on the performance of mpUSS derived 
targeted biopsies in the identification of clinically significant prostate cancer in comparison to 
mpMRI targeted biopsies. Recruitment is underway and expected to complete in 2018. 
 
Keywords: CADMUS, prostate cancer, multiparametric ultrasound, multiparametric MRI, 
targeted prostate biopsy, TRUS 
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Introduction 
 
The diagnostic pathway for prostate cancer is one that offers significant opportunities  for 
improvement. The lack of an accurate biomarker[1] means that confirmation of disease is 
dependent upon a positive tissue diagnosis and the international standard remains an 
unguided systematic transrectal prostate biopsy[2]. Standard TRUS biopsy does not sample 
the prostate either systematically or reliably[3,4]. 
 
Multiparametric MRI offers a great deal in terms of potential improvements to this pathway. 
Recently published reports have estimated the negative predictive value of mpMRI to be 79% 
for prostate cancer containing any grade 4 disease with a maximum cancer core length of 
4mm (UCL definition 2), and a NPV of 90-95% for dominant pattern grade 4 with any cancer 
core length greater than 6mm or both (UCL definition 1)[5]. Level 1 evidence has now been 
provided in the first report from the PROMIS trial[6] showing a sensitivity of 93% for MRI 
versus 48% for systematic TRUS in the detection of clinically significant disease. MRI targeted 
transperineal biopsies have been reported as showing equivalence to transperineal mapping 
biopsies but with a greatly reduced pathological burden and detection rate for clinically 
insignificant prostate cancer[7] as well as offering a rate of post biopsy septicaemia which 
approaches zero[8]. 
 
Pre biopsy MRI scanning is latterly the recommendation of some guidelines[9] but its status 
as a second tier investigation, suggested only for men with a previous negative prostate 
biopsy, is likely a reflection of its significant disadvantages in cost and availability. MRI scans 
for suspected prostate cancer can cost £350-400, double the cost of mpUSS, in the UK system 
and many multiples of that elsewhere with US estimates of between USD1,000-3,000. Some 
of the published data relies upon 3 Tesla machines, largely unavailable outside of specialist 
units, and that require lengthy and cost intensive sequences. A small but significant number 
of patients are unsuited to MRI because of metal prostheses or claustrophobia. 
 
Ultrasound has long been employed to guide prostate biopsies and is a technique familiar to 
most urologists. More recent developments in the technology include elastography where 
tissue response to compression, either by the operator or by use of a focussed ultrasound 
pulse in the shear wave variant, is displayed as a coloured overlay for the B-mode imaging. 
The increased tissue density of malignancy, a phenomenon widely accepted in clinical  
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examination, has been related in the lab to increased cell density and differing collagen 
distribution.[10,11] Contrast enhanced ultrasound is another form of ultrasound whereby 
injection of an agent such as sulphur hexafluoride microbubbles can highlight areas of 
increased vascularity. Software for the quantitative interpretation of the resultant images is in 
development. Substantial trials of these technologies remain scarce but encouraging results 
have emerged from some recent, smaller series[12],. It seems that the combination of these 
various parameters of ultrasound (B-mode, power Doppler, elastography and contrast-
enhanced) in a similar fashion to the way in which mpMRI incorporated T2-weighted, 
diffusion and contrast enhancement to improve accuracy of cancer detection, might be the 
key[13]. 
 
 
 
 
 
 
 
Trial information 
 
 
CADMUS is a prospective, multi centre paired cohort study assessing diagnostic utility. It will 
include independent blind reporting of each scanning technique and randomisation of biopsy 
order. The UCL Surgical and Interventional Trials Unit is responsible for the maintenance of 
good clinical practice within the trial. CADMUS was granted ethics committee approval by the 
London (Brent) Health Research Authority Ref 15/LO/1331 and is registered with the ISRCTN 
(ISRCTN38541912). 
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Figure 1. Doppler (fine flow CFI) showing suspicious signal in left peripheral zone (circled).  
 
Subsequent biopsies confirmed Gl 3+4 7mm in this area. 
 
 
 
 
Study Objectives 
 
Primary 
 
To determine the overall agreement in identifying lesions to biopsy between multi-parametric 
ultrasound and multi-parametric MRI in men who are at risk and normally recommended for 
a prostate biopsy; to then compare the overall agreement in the proportions of men 
diagnosed with clinically significant prostate cancer on biopsy. 
 
 
 
 
Clinically significant prostate cancer for the purpose of the primary objective will be defined 
by UCL/Ahmed definition 1 (Gleason >/=4+3 and/or maximum cancer core length >/=6mm). 
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Secondary 
 
To compare the overall agreement in proportions of men diagnosed with other thresholds of 
clinically significant prostate cancer on biopsy, namely 
 
- UCL/Ahmed definition 2: Gleason >/=3+4 and/or maximum cancer core length 
>/=4mm 
 
- Gleason >/=3+4 and/or MCCL >/=6mm 
 
- Any length of Gleason >/=3+4 
Any length of Gleason >/=4+3 
 
To determine the detection of clinically significant cancer (using all of the pre-specified 
definitions based on histology) by using the combination of both mpUSS and mpMRI 
techniques versus either modality alone 
 
To determine whether the order in which the targeted biopsies are carried out, either to the 
same target (present on both scans) or different targets impacts on detection of clinically 
significant cancer (using all of the pre-specified definitions based on histology) 
 
To compare, in those men who go on to radical prostatectomy, the mpMRI, mpUSS and 
histology from targeted biopsy with the whole mount specimen obtained at surgery. 
 
To determine rates of adverse events, resource utilization and impact of each test on health-
related quality-of-life using the EQ-5D-5L questionnaire. 
 
To create an inception cohort of men, consented for long-term follow-up and linkage, 
providing the potential for further translational and clinical studies. 
 
 
 
 
Study Population 
 
 
The study participants will be drawn from those men at risk referred to one of the study 
centres who are normally recommended to need a prostate biopsy, either as new 
presentations with an elevated PSA or who have previously undergone prostate biopsy with 
either a positive or negative result but require more accurate risk stratification. Table 1 shows 
inclusion and exclusion criteria. 
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Table 1. Eligibility criteria for the CADMUS trial. 
 
 
Inclusion Criteria 
 
 
1. A potential need for prostate biopsy indicated by raised PSA or other clinica 
parameter, the final decision over which will be taken after imaging. 
  
2.  PSA </=20ng/ml measured within 6 months of screening visit  
 
 
 
3. An understanding of the English language sufficient to understand written 
and verbal information about the trial and consent process  
 
 
 
4.  Estimated life expectancy of 5 years or more 
 
 
5.  Signed informed consent 
 
 
 
 
 
 
 
 
Exclusion  
 
Criteria 
 
1. Any contraindication to the ultrasound contrast agent including right to left 
shunt, pulmonary hypertension and uncontrolled hypertension. Also 
patients with an acute coronary syndrome within the last 6 months or 
ischaemic heart disease that’s not well controlled by medication.  
  
2. Any form of hormone manipulation or androgen deprivation therapy 
(except 5-alpha reductase inhibitors) within 6 months of screening visit 
  
3.  Irreversible coagulopathy predisposing to bleeding 
 
 
 
 
 
 4. Inability to undergo transrectal ultrasonography 
  
 5. Prostate volume, measured at the time of mp-USS if previously  unknown, 
 of >60cc 
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6.  Previous radiation therapy to the prostate 
 
7. Previous HIFU, cryosurgery, thermal therapy, irreversible 
electroporation, photodynamic, photothermal therapy, microwave or 
injectable toxin therapy to the prostate. 
 
 
 
8. Transurethral resection or vaporization of the prostate for benign prostatic 
hyperplasia using any energy modality within 6 months of screening visit  
  
9. Nodal or metastatic prostate cancer on any form of imaging 
at any time-point 
 
 
10. Not fit for general anaesthetic  
 
 
11. Unable to give informed consent 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This is a heterogenous group of men which aims to impart external validity to this study of 
diagnostic utility by better reflecting clinical practice than a narrower population. An upper 
prostate volume threshold of 60cc was chosen to maintain ultrasound image quality in the 
anterior gland in b-mode as well as to avoid a drop off in the utility of elastography 
anticipated in larger prostates. 
 
 
 
 
Diagnostic imaging 
 
All men recruited to CADMUS will receive both mpMRI and mpUSS scans. Suspicious lesions 
on either imaging type will be subjected to targeted biopsy. 
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Multiparametric MRI 
 
Pre biopsy MRI is standard of care at the CADMUS study sites and comprises high resolution 
T2, diffusion weighted imaging (DWI) and gadolinium dynamic contrast enhanced sequences 
compliant with European Society of Uro-Radiology[14] and the British Society of Uro-
Radiology[15]. DWI includes the generation of apparent diffusion coefficient (ADC) maps as 
well as images with a high b value of >1000. A variety of 1.5 and 3 Tesla machines are in use 
across the study sites, again allowing the trial population to reflect wider clinical practice. All 
MRIs will be reported by experienced Uro-Radiologists who are compliant with the standards 
laid down by the British Society of Uro-Radiology (BSUR). Lesions identified with a radiological 
score of 3, 4 or 5 would normally be subjected to targeted biopsy. Scores for both mpMRI and 
mpUSS reporting will be based on a Likert scale from 1 to 5, with 1 signifying a high likelihood 
of benign tissue and 5 a high likelihood of malignancy. 
 
Multiparametric Ultrasound 
 
The multiparametric ultrasound scan used in CADMUS has been developed to allow capture 
and image analysis that is in some respects analogous to that achieved with mp-MRI. Trial 
participants will first have prostate volume estimation from linear dimensions and those 
calculated at greater than 60cc, if the volume was previously unknown, will be excluded. The 
prostate is then examined using the 4 principal scanning modalities sequentially. All scans are 
recorded then exported as DICOM (mpeg) files for detailed later analysis and attention is paid 
to the slow capture of images along anatomical axes through the whole length of the 
prostate. This allows for frame-by-frame analysis in a manner analogous the slices produced 
by MRI and the side-by-side comparison of images produced by the various ultrasound 
technologies at the same anatomical position. 
 
B-mode images are captured in both oblique axial and saggital  planes and the other 
ultrasound modes predominantly in the axial plane to avoid excessive scanning times. Both 
colour and high frequency or fine flow Doppler images are captured separately. 
 
Real time elastography is employed to gather information about tissue response to slight 
compression by the probe with stiffer tissue displayed in blue and less stiff in red (Figure 2). 
Scanning is carried out stepwise through the prostate in an oblique axial plane with pauses  
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every few mm to allow the elastogram to stabilise.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Decreased tissue elasticity in the right posteriolateral prostate which at biopsy 
revealed 3mm Gl 3+4 
 
 
 
 
Finally contrast enhanced ultrasound is employed in two stages. First, the area of the prostate 
so far considered most suspicious is brought into view in the axial plane and after video 
recording begins a bolus of SonoVue®™ microbubble contrast is injected through an 
intravenous cannula in response to a countdown triggered on screen (figure 3). Once the 
prostate is fully perfused with contrast and an examination time of more than 45 seconds is 
reached the first video is saved. A second recording is made using flashes of high powered 
ultrasound energy to burst the bubbles in the immediate field, allowing for reperfusion with 
the image focused on a new part of the prostate. In this way, some contrast perfusion 
information can be obtained for the whole prostate despite the limitation of our TRUS probes 
to the capture of 2 dimensional images. The authors consider these reperfusion sequences to 
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be less valuable than the first for the identification of early contrast enhancement as the 
wash in phase is less pronounced. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. A large area of pronounced early contrast enhancement in the left anterior 
prostate. Biopsy revealed 15mm of Gl 4+3 adenocarcinoma. 
 
 
 
 
Quantitative analysis of the CEUS videos is carried out remotely after the scan. This relies on 
a recently developed technique by Bracco Suisse SA (Geneva, Switzerland) which is based on 
a statistical analysis of parametric maps of Wash-in Rate (WiR), a perfusion parameter 
reflecting the rate of contrast enhancement. The parametric maps are generated by 
analysing time-intensity curves (TIC) representing the echo-power as a function of time, on 
a pixel-by-pixel basis. 
 
The characteristics of each pixel on the parametric map are determined by an analysis of the 
WiR histograms from it and immediately surrounding pixels, incorporating statistical 
parameters such as mode and standard deviation (SD). The resulting map uses colour coding 
to display the probability of PCa occurrence. The classification criteria are derived from 
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analysis of 42 regions of interest containing PCa on whole mount prostatectomy 
histopathology[16]. 
 
Lesions identified on mpUSS will have a Likert type score generated for each of the above 
ultrasound technologies and an overall score for each lesion. As with mpMRI, scores of 3 or 
more will be targeted at biopsy. The reporting proforma allows lesions to be localised to one 
of 12 sectors produced by dividing the prostate into apical, midgland and basal segments 
and then each of these into left/right and anterior/posterior quandrants. 
 
 
 
 
Trial Biopsy 
 
The cognitively targeted transperineal prostate biopsy employed by the CADMUS trial is an 
adaption of the standard of care biopsy at the authors’ institutions. Performed in an 
operating theatre or procedure room under local anaesthetic with or without intravenous 
sedation, or general anaesthetic, the patient is placed in the lithotomy position and 3 
targeted biopsies are taken using a brachytherapy template grid. Block randomisation is be 
used to determine whether mpUSS or mpMRI derived targets will be sampled first. This step 
aims to avoid any skewing of the results that might be caused by a fixed biopsy order, where 
specimens taken later in the procedure may be subject to increased targeting error caused 
by swelling or haemorrhage stemming from the earlier biopsies. This phenomenon, if 
present, will also be identifiable in our results. 
 
 
 
 
Statistical considerations 
 
 
Power calculations for CADMUS were generated using the following underlying 
assumptions. The rate of identification of men with a lesion to biopsy by mpMRI, based on 
data from the PICTURE16 study was 80%. A prevalence of 30% of men amongst the biopsy 
population with clinically significant disease (UCL/Ahmed definition 1) was considered likely. 
Assuming slightly lower rate of identification of lesions for biopsy by mpUSS (75%) and that 
90% of those cases have the same lesion identified by mpMRI then one should expect to 
achieve a confidence level of 95% with 450 men recruited and 275 of those proceeding as  
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far as biopsy. Higher figures for cancer detection or agreement between the two imaging 
techniques will require a smaller number of recruits to achieve the same degree of 
confidence. 
 
The primary outcome for the trial will be calculated by comparing proportions of men 
diagnosed with clinically significant prostate cancer by mpUSS or mpMRI using McNemar’s 
test. A full statistical analysis plan will be developed with the results of the pilot in hand. 
 
 
 
 
Outcome measures 
 
Table 2. Outcome measures for the CADMUS trial 
 
 
Primary  
 
 
 
 
 
The proportion of men with a lesion detected using each diagnostic strategy and the 
proportion of men subsequently diagnosed with clinically significant prostate cancer as 
defined histologically as UCL/Ahmed definition 1 (Gleason 4+3 or greater and/or 
maximum cancer core length of 6mm or greater). 
 
 
Secondary 
  
The proportion of men diagnosed with clinically significant prostate cancer by each 
diagnostic strategy as defined histologically using other thresholds for clinical significance, 
namely; 
 
 
- UCL/Ahmed definition 2: Gleason >3+4 and/or maximum cancer core length >4mm 
 
- Gleason >3+4 and/or MCCL >6mm 
 
- Any length of Gleason >3+4 
 
- Any length of Gleason >4+3  
 
 
 
The proportion of men diagnosed with clinically significant cancer (using all of the pre-
specified definitions based on histology) by using the combination of these two imaging  
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techniques versus either modality alone. 
 
 
 
The proportion of men diagnosed with clinically significant prostate cancer (using all of 
the pre-specified definitions based on histology) when 
 
- mp-USS targeted biopsies are carried out first compared to being carried out 
second 
 
- mp-MRI targeted biopsies are carried out first compared to being carried 
out second. 
 
 
The proportion of men from the cohort who progress to radical prostatectomy, and 
have whole mount histology that matches the results of the mp-USS, mp-MRI and 
targeted biopsy. 
 
 
Proportions of adverse events and health-related quality-of-life measures on the EQ-5D-5L 
questionnaire. 
 
 
A cohort of men, consented for long-term follow-up and linkage, providing the potential 
for further translational and clinical studies. 
 
 
Table 2. Outcome measures for the CADMUS trial. 
 
 
 
 
 
Trial outcomes for CADMUS may be seen in table 2 and tally with the objectives outlined. 
The question of clinical significance in prostate cancer remains one of controversy and is 
worthy of consideration. The contrast between reports from post mortem studies that some 
50% of men will have detectable prostate cancer over the age of 50[17] and the population 
mortality from the disease of 3[18] makes it apparent that much of diagnosed prostate 
cancer may not threaten life. Level one evidence from the Prostate Cancer Intervention 
Versus Observation Trial (PIVOT)[19] demonstrated that men with lower risk prostate cancer 
did not benefit from treatment and the more recent ProtecT[20] trial, in which about three-
quarters of men had low risk disease, showed no significant difference in mortality 
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between men with prostate cancer randomised to either surgery, radiotherapy or active 
monitoring. The existence of at least some prostate cancer that is not clinically significant is 
now widely accepted. 
 
Relative consensus on the need for a definition of clinical significance is of course no 
guarantee of agreement on what it should be. The debate is further coloured by the 
apparent improvement in the performance of imaging or targeted biopsy studies that stems 
from the use of a higher threshold of grade and stage for significance, versus the boost that 
a lower threshold will add to the apparent performance of systematic biopsy. 
 
For CADMUS the investigators aim to bypass much of this controversy by reporting at many 
thresholds including the detection of any prostate cancer and definitions independent 
either of Gleason grade or tumour volume (core length). A definition was needed for the 
primary outcome and UCL definition 1 (presence of any primary pattern 4 disease and/or 
maximum cancer core length of >6mm) was chosen. This has its basis in the proposal that 
cancers of 0.5cm
3
 are likely to be significant[21] supported by more recent data from the 
European Prostate Cancer Screening trial[22]. This volume of tumour and a core length at 
biopsy of 6mm have been shown to correlate by computer modelling studies performed at 
this institution[23] and is the same as that used in the recently reported PROMIS and 
PICTURE trials[6,24]. 
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Trial flow 
 
CADMUS trial flow is shown in figure 4 
 
 
 
 
Men with a potential need for prostate biopsy indicated by raised 
PSA or other clinical parameter. 
 
 
 
Invitation to take part and information sheet sent to patient 
 
 
 
Telephone call by research team after 24hrs post invitation 
to discuss study 
 
 
 
Visit 1 (During standard care visit day) 
Screening & Consent 
If ICF signed: multi-parametric ultrasound scan 
Adverse events, EQ-5D-5L 
 
 
 
 
Visit 2 (Standard care)  
Multi-parametric MRI scan (if not done within 6 months of consent)  
Adverse events, EQ-5D-5L 
 
 
 
 
Visit 3 (Standard care) 
Targeted prostate biopsies under LA with optional sedation if those with  
suspicious imaging 
Adverse events, EQ-5D-5L 
 
 
 
 
 
Visit 4 (During standard care visit day)  
Adverse events, EQ-5D-5L (results given by clinical team) 
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Discussion 
 
 
CADMUS uses a multicentre paired cohort design with all patients undergoing both scans 
and the reporters of each scan blind to the results of the other, eliminating much potential 
bias. It will represent diagnostic level one evidence. The patient is also blind to the imaging 
origin of the lesion that triggered the biopsy procedure minimising work up bias and the 
potential attrition of recruits who had a negative MRI scan but a biopsy indicated on the 
grounds of the trial (mpUSS) scan alone. 
 
The trial design has some potential limitations, the first of which is the comparison of only 
targeted biopsies between imaging modalities, rather than the employment of a template 
mapping biopsy as a reference standard. This has the disadvantage of precluding the 
analysis of true and false negatives generated by the scans which would be possible had 
patients undergone both targeted and systematic biopsies. CADMUS is designed as a clinical 
utility study to explore the potential for mpUSS to perform some or all of the role that 
mpMRI fills at this and other institutions. The authors’ unit having transitioned already to a 
policy of targeted only biopsies for most patients (cases with doubt over imaging or 
diagnosis will still undergo systematic biopsy), it was judged that the increase in pathological 
burden, operating time and biopsy complications that would come with a return to universal 
systematic biopsy would be unreasonable when considering negative predictive values of 
90-95%. Added to the case for a targeted only study was evidence showing equivalence in 
diagnostic performance for the two techniques[7] 
 
Another potential criticism might be directed at the use of cognitive (visually estimated) 
registration of imaging derived targets for biopsy, rather than the use of an image fusion 
system. The choice of cognitive registration, standard practice among biopsy surgeons at 
our units, was driven by the impracticalities of fusing mpUSS derived targets with the same 
precision as those from mpMRI and supported by reports on the performance of targeted 
only biopsy using cognitive registration[25]. The lack of a system to accurately fuse 
diagnostic mpUSS images with live ultrasound during biopsy had one further ramification, 
the removal of the planned blinding of the biopsy surgeon to the provenance of the lesion 
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to be biopsied. This would be impossible as cognitive registration relies upon review of the 
relevant images at the time of biopsy. 
 
Conclusions 
 
CADMUS is a multicentre diagnostic paired cohort study that will provide the first level one 
evidence on the clinical utility of multiparametric ultrasound in prostate cancer diagnosis, 
specifically in the context of targeted prostate biopsy, in comparison to mpMRI targeted 
biopsies. If mpUSS is demonstrated to have value in the diagnostic pathway it may have a 
role to play in spreading the use of imaging in the detection of prostate cancer and 
offsetting some of the significant economic barriers to the universal provision of a 
pathway based solely on MRI. 
 
CADMUS is open to recruitment at centres in the UK and expected to complete 
recruitment in early 2018. 
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